Table 1 Clinical characteristics and ophthalmic data of control subjects and patients with central retinal vein occlusion.

From: Differential expression of aqueous humor microRNAs in central retinal vein occlusion and its association with matrix metalloproteinases: a pilot study

 

M/F

Age (y)

Diagnosis

Laterality

Underlying diseases

CMT (μm)

BCVA (logMAR)

IOP (mmHg)

SE (D)

miRNA PCR array

Gel zymography

Control

1

F

65

Cataract

OD

HTN

n/a

0.30

15

− 1.25

 

2

F

63

Cataract

OD

(–)

n/a

0.52

19

− 0.25

 

3

F

65

Cataract

OD

(–)

n/a

0.22

16

0.00

 

4

F

62

Cataract

OD

(–)

n/a

0.00

17

− 0.50

 

5

M

66

Cataract

OS

(–)

n/a

0.30

17

− 4.50

 

6

F

65

Cataract

OD

HTN

n/a

0.15

15

− 4.50

 

7

M

56

Cataract

OD

(–)

n/a

0.40

15

− 0.50

 

8

F

70

Cataract

OD

HTN

n/a

0.10

14

− 0.50

 

CRVO

1

M

62

CRVO

OD

HTN, Dyslipidemia

603

0.52

12

0.50

 

2

F

75

CRVO

OS

HTN, Unstable angina

567

0.30

13

− 0.25

 

3

F

63

CRVO

OS

Dyslipidemia

802

1.00

18

1.00

 

4

M

75

CRVO

OS

HTN

550

0.70

10

0.00

 

5

M

52

CRVO

OD

HTN

657

1.10

15

0.00

 

6

M

68

CRVO

OD

HTN

836

0.30

18

− 0.50

 

7

M

76

CRVO

OD

(–)

486

0.70

19

− 1.00

 

8

F

43

CRVO

OS

(–)

445

0.30

11

− 1.00

 

9

M

78

CRVO

OS

HTN

629

1.00

16

− 1.50

 

10

F

61

CRVO

OD

HTN, Dyslipidemia

391

1.00

12

0.75

 

  1. BCVA, Best-corrected visual acuity; CMT, central macular thickness; CRVO, central retinal vein occlusion; HTN, hypertension; IOP, intraocular pressure; n/a, not applicable; SE, spherical equivalent.